Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Access Programs

Disease Information

Descriptive Information
Brief Title † Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Official Title † Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.
Brief Summary A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
Detailed Description This is a multicenter, prospective phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Trabectedin given with durvalumab, followed by two expansion cohorts once the MTD is established.
Study Phase Phase 1
Study Type † Interventional
Study Design †
Primary Outcome Measure † Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D21) of Trabectedin when administered in association with Durvalumab
Secondary Outcome Measure † Recommended phase II dose (RP2D) of the association of Trabectedin and given in combination with Durvalumab
Condition † Ovarian Carcinoma Soft Tissue Sarcoma
Intervention † DrugCombination of trabectedin with durvalumab
Study Arms / Comparison Groups Combination of trabectedin with durvalumab Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level. Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Drug
Estimated Enrollment † 50
Start Date † May 5, 2017
Completion Date May 5, 2021
Primary Completion Date May 5, 2020
Eligibility Criteria † Inclusion Criteria: 1. Histology : - Soft-tissue sarcoma histologically confirmed. In care outside a center of the RRePS Network, a central review is necessary (Pr. Coindre team), - histologically confirmed ovarian carcinoma (carcinosarcoma included), 2. or ovarian carcinoma without known g/s BRCA mutation and: - platinum sensitive ovarian carcinoma relapses (> 12 months) non suitable for platinum rechallenging treatment, - or intermediate platinum sensitive ovarian carcinoma relapses (6-12 months). 3. Metastatic or unresectable locally advanced disease, 4. Age ≥ 18 years, 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1, 6. Life expectancy > 3 months, 7. Patients must have measurable disease (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST 1.1) defined as per RECIST v1.1 with at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as > 10 mm with spiral CT scan. 8. Documented disease progression according to RECIST v1.1 before study entry, 9. Patient must comply with the collection of tumor biopsies, 10. At least 1 line of chemotherapy in the palliative setting with use of Anthracyclines (for STS), or platinum containing regimen (for ovarian carcinoma), 11. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy, 12. Adequate hematological, renal, metabolic and hepatic function: 1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell [RBC] transfusion, if clinically indicated); absolute neutrophil count (ANC) ≥ 1.5 x 109/l, and platelet count ≥ 100 x 109/l. 2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normality (ULN) (≤ 5 in case of extensive liver involvement) and alkaline phosphatase (AP) ≤ 2.5 x ULN. 3. Total bilirubin ≤ ULN. 4. Albumin ≥ 25 g/l. 5. Calculated creatinine clearance (CrCl) > 40 ml/min (according to Cockroft Gault formula). 6. Thyroid function within normal laboratory ranges (TSH, free T3, free T4). 13. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of trial medication. Both women and men must agree to use a highly effective method of contraception throughout the treatment period and for six months after discontinuation of treatment. Acceptable methods of contraception are described in protocol section, 14. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma, 15. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment (excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0), 16. Voluntarily signed and dated written informed consent prior to any study specific procedure, 17. Patients with a social security in compliance with the French law relating to biomedical research (Article 1121-11 of French Public Health Code). Exclusion Criteria: 1. Previous treatment with Trabectedin or an anti-PD-1, anti-PD-L1, anti-PD-L2, including durvalumab 2. Current or prior use of immunosuppressive medication medication including any use of oral glucocorticoids, within 21 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses 3. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), 4. Has an active autoimmune disease requiring systemic treatment within the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insuddiciency) is not considered a form of systemic treatment, 5. Has evidence of active non-infectious pneumonitis, 6. Has an active infection requiring systemic therapy, 7. Currently active bacterial or fungus infection (> grade 2 CTC [CTCAE] HIV1, HIV2, hepatitis A or hepatitis B or hepatitis C infections, 8. Known central nervous system malignancy (CNS), 9. Men or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding, 10. Previous enrolment in the present study, 11. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons, 12. Has received a live vaccine within 30 days prior to the first dose of trial treatment. Note: the killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. 13. Known hypersensitivity to any involved study drug or any of its formulation components, 14. Tumors not accessible for biopsy, 15. Known history of active tuberculosis
Gender All
Ages 18 Years - N/A
Accepts Healthy Volunteers No
Contacts †† Maud TOULMONDE, MD, +556333333,
Location Countries † France
Administrative Information
NCT ID † NCT03085225
Organization ID IB2016-02
Secondary IDs ††
Responsible Party Sponsor
Study Sponsor † Institut Bergonié
Collaborators †† AstraZeneca
Investigators † : ,
Information Provided By
Verification Date May 2017
First Received Date † March 15, 2017
Last Updated Date May 12, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
Free Newsletter